Literature DB >> 11085938

Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9.

Y Shi1, M Zou, N R Farid, M C Paterson.   

Abstract

FHIT (fragile histidine triad), a candidate tumour suppressor gene, has recently been identified at chromosomal region 3p14.2, and deletions of the gene have been reported in many types of human cancer. However, the biological function of the Fhit protein has not been fully characterized yet. Using the yeast two-hybrid screen to search for proteins that interact with Fhit in vivo, we identified a protein that is specifically associated with Fhit. This association was confirmed in both immunoprecipitation and glutathione S-transferase pull-down assays. The sequence of the protein is identical with that of human ubiquitin-conjugating enzyme 9 (hUBC9). The last 21 amino acids at the C-terminus of hUBC9 appear to be unimportant for its biological activity, since an hUBC9 mutant harbouring a deletion of these amino acids could still restore normal growth of yeast containing a temperature-sensitive mutation in the homologue UBC9 gene. Mutational analysis indicated that hUBC9 was associated with the C-terminal portion of Fhit. Neither a single amino acid substitution at codon 96 (His-->Asn) nor triple amino acid substitutions (His-->Asn) at a histidine triad (codons 94, 96 and 98) affected the association, whereas Fhit triphosphate (diadenosine 5',5"'-P(1),P(3)-triphosphate) hydrolase activity has been reported to be eliminated by either type of mutation, suggesting that the interaction between Fhit and hUBC9 is independent of Fhit enzymic activity. Given that yeast UBC9 is involved in the degradation of S- and M-phase cyclins, Fhit may be involved in cell cycle control through its interaction with hUBC9.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085938      PMCID: PMC1221476     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  35 in total

1.  Variable FHIT transcripts in non-neoplastic tissues.

Authors:  I Panagopoulos; S Thelin; F Mertens; F Mitelman; P Aman
Journal:  Genes Chromosomes Cancer       Date:  1997-08       Impact factor: 5.006

2.  Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin.

Authors:  T Okura; L Gong; T Kamitani; T Wada; I Okura; C F Wei; H M Chang; E T Yeh
Journal:  J Immunol       Date:  1996-11-15       Impact factor: 5.422

3.  Direct involvement of the ubiquitin-conjugating enzyme Ubc9/Hus5 in the degradation of IkappaBalpha.

Authors:  K Tashiro; M P Pando; Y Kanegae; P M Wamsley; S Inoue; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

4.  Degradation of E2A proteins through a ubiquitin-conjugating enzyme, UbcE2A.

Authors:  C J Kho; G S Huggins; W O Endege; C M Hsieh; M E Lee; E Haber
Journal:  J Biol Chem       Date:  1997-02-07       Impact factor: 5.157

5.  A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2.

Authors:  R Mahajan; C Delphin; T Guan; L Gerace; F Melchior
Journal:  Cell       Date:  1997-01-10       Impact factor: 41.582

6.  Replacement of Fhit in cancer cells suppresses tumorigenicity.

Authors:  Z Siprashvili; G Sozzi; L D Barnes; P McCue; A K Robinson; V Eryomin; L Sard; E Tagliabue; A Greco; L Fusetti; G Schwartz; M A Pierotti; C M Croce; K Huebner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

7.  Association of human fas (CD95) with a ubiquitin-conjugating enzyme (UBC-FAP).

Authors:  D A Wright; B Futcher; P Ghosh; R S Geha
Journal:  J Biol Chem       Date:  1996-12-06       Impact factor: 5.157

8.  mUBC9, a novel adenovirus E1A-interacting protein that complements a yeast cell cycle defect.

Authors:  G Hateboer; E M Hijmans; J B Nooij; S Schlenker; S Jentsch; R Bernards
Journal:  J Biol Chem       Date:  1996-10-18       Impact factor: 5.157

9.  Molecular cloning of the cDNA and chromosome localization of the gene for human ubiquitin-conjugating enzyme 9.

Authors:  Z Y Wang; Q Q Qiu; W Seufert; T Taguchi; J R Testa; S A Whitmore; D F Callen; D Welsh; T Shenk; T F Deuel
Journal:  J Biol Chem       Date:  1996-10-04       Impact factor: 5.157

10.  Molecular characterization of the SUMO-1 modification of RanGAP1 and its role in nuclear envelope association.

Authors:  R Mahajan; L Gerace; F Melchior
Journal:  J Cell Biol       Date:  1998-01-26       Impact factor: 10.539

View more
  14 in total

Review 1.  Hits, Fhits and Nits: beyond enzymatic function.

Authors:  Kay Huebner; Joshua C Saldivar; Jin Sun; Hidetaka Shibata; Teresa Druck
Journal:  Adv Enzyme Regul       Date:  2010-10-28

2.  Immunohistochemical characterization of FHIT expression in normal human tissues.

Authors:  Omar Kujan; Abdulwahab Abuderman; Ahmad Zahi Al-Shawaf
Journal:  Interv Med Appl Sci       Date:  2016-03

3.  Distribution of Fhit protein in rat tissues and its intracellular localization.

Authors:  F Golebiowski; R Kowara; T Pawelczyk
Journal:  Mol Cell Biochem       Date:  2001-10       Impact factor: 3.396

4.  Reduced Fhit protein expression in nickel-transformed mouse cells and in nickel-induced murine sarcomas.

Authors:  Renata Kowara; Konstantin Salnikow; Bhalchandra A Diwan; Robert M Bare; Michael P Waalkes; Kazimierz S Kasprzak
Journal:  Mol Cell Biochem       Date:  2004-01       Impact factor: 3.396

5.  Fhit is a physiological target of the protein kinase Src.

Authors:  Yuri Pekarsky; Preston N Garrison; Alexey Palamarchuk; Nicola Zanesi; Rami I Aqeilan; Kay Huebner; Larry D Barnes; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-08       Impact factor: 11.205

Review 6.  Fhit tumor suppressor: guardian of the preneoplastic genome.

Authors:  Flavia Pichiorri; Tiziana Palumbo; Sung-Suk Suh; Hiroshi Okamura; Francesco Trapasso; Hideshi Ishii; Kay Huebner; Carlo M Croce
Journal:  Future Oncol       Date:  2008-12       Impact factor: 3.404

7.  Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells.

Authors:  Francesco Trapasso; Flavia Pichiorri; Marco Gaspari; Tiziana Palumbo; Rami I Aqeilan; Eugenio Gaudio; Hiroshi Okumura; Rodolfo Iuliano; Giampiero Di Leva; Muller Fabbri; David E Birk; Cinzia Raso; Kari Green-Church; Luigi G Spagnoli; Salvatore Venuta; Kay Huebner; Carlo M Croce
Journal:  J Biol Chem       Date:  2008-03-03       Impact factor: 5.157

Review 8.  Fragile histidine triad protein: structure, function, and its association with tumorogenesis.

Authors:  Md Imtaiyaz Hassan; Abdullah Naiyer; Faizan Ahmad
Journal:  J Cancer Res Clin Oncol       Date:  2009-12-24       Impact factor: 4.553

9.  Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential.

Authors:  S Semba; F Trapasso; M Fabbri; K A McCorkell; S Volinia; T Druck; D Iliopoulos; Y Pekarsky; H Ishii; P N Garrison; L D Barnes; C M Croce; K Huebner
Journal:  Oncogene       Date:  2006-05-11       Impact factor: 8.756

10.  The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions.

Authors:  G Terry; L Ho; P Londesborough; C Duggan; A Hanby; J Cuzick
Journal:  Br J Cancer       Date:  2006-12-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.